The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Primary analysis of MURANO study data for R/R CLL
Updates from the highly anticipated Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. In this interview, John Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, Australia, discusses the results from first released data of the primary analysis of MURANO, which he presented as a late-breaking abstract at the meeting. Read more about the results here: https://ash.confex.com/ash/2017/webprogram/Paper109076.html
